Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
